@I , it would be great if it was confirmed that it was the NIH but to either way, to have a strategic partner get on board any ARDS trial would show again (for those who need showing) that Novartis pulling out was due to their own strategic decisions rather than anything to do with what we can achieve. It is still important enough for him to mention EUA. ARDS whether Covid or other reasons (including a new pandemic) is going to provide plenty of need. Inflammation and Mesoblast will become synonymous in the medical community in the next few years, with a share rating to match.
Ann: MSB Presents at Edison Group Global Healthcare Conference, page-55
-
- There are more pages in this discussion • 213 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.17 |
Change
0.045(4.00%) |
Mkt cap ! $1.335B | |||
| Open | High | Low | Value | Volume |
| $1.13 | $1.18 | $1.13 | $4.980M | 4.315M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 4 | 73090 | $1.15 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.17 | 27903 | 1 |
View Market Depth
| Last trade - 16.10pm 30/09/2024 (20 minute delay) ? |
| MSB (ASX) Chart |